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Abstract
Background: Macrophage activation syndrome is described as a “clinical syndrome of hyperinflammation resulting
in an uncontrolled and ineffective immune response” in the context of an autoinflammatory or rheumatic disease.
Current associations of macrophage activation syndrome with autoimmune disease most notably include a host of
rheumatological conditions and inflammatory bowel disease. Epidemiological studies have shown that macrophage
activation syndrome is precipitated by autoimmune disease more commonly than previously thought. Diagnosing
the precipitating factor is essential for effective treatment and prognosis.
Case presentation: We report a case of a six year old girl with coeliac disease diagnosed after two episodes of
secondary haemophagocytic lymphohistiocytosis. Her condition only responded to treatment once the patient was
placed on a gluten free diet. Further immunological testing confirmed anti-transglutaminase and anti-endomysial
antibodies, however histological biopsy was deemed inappropriate due to the severity of her condition. She has
remained stable with no further episodes of macrophage activation syndrome since commencing a gluten free diet.
Conclusion: This case report is the first literature that links macrophage activation syndrome to coeliac disease and
highlights the challenge of diagnosing coeliac disease with unusual features such as associated prolonged fever.
Clinicians should have a low threshold for screening children with other autoimmune diseases for coeliac disease.
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Background
Macrophage activation syndrome (MAS) is a serious
complication of autoimmune disease with epidemiological
reports of 4.2% in known cases of Juvenile Idiopathic
Arthritis (JIA) and Systemic Lupus Erythematosus (SLE)
[1]. Multiple reports have described MAS complicating a
number of other autoimmune and auto-inflammatory dis-
eases such as Kawasaki Disease [2, 3], Periodic fever syn-
dromes [4] and inflammatory bowel disease [5, 6]. The
significant mortality associated with the condition makes
early diagnosis and early management important. Even
with treatment using high dose steroids and biologics, pa-
tients with MAS complicating systemic-onset JIA (SoJIA)
required intensive care in 34.9% and had an associated
mortality of 8.1% [7]. A number of epidemiological studies
have shown that MAS may be more common in auto-
immune disease than previously thought [8–10].
Haemophagocytic lymphohistiocytosis (HLH) is defined
by the 2004 criteria as molecular manifestations of known
genetic defects (such as in perforin gene or Munc 13–4
gene) and clinical features. [11] MAS has a slightly different
definition to HLH by not have a genetic component, as
illustrated by the 2016 classification in SoJIA [12]. The
presentation of MAS can often mimic the underlying
systemic condition, with a rapid onset of persistent fever,
reduced cognitive state, hepatosplenomegaly, lymphaden-
opathy, liver dysfunction and haemorrhagic skin manifesta-
tions. These features are found in conjunction with a fall in
at least two haematological lineages, resulting in anaemia,
thrombocytopenia or neutropenia, caused by an increased
consumption and phagocytosis of the cells in the bone
marrow.
The pathology behind MAS has been suggested by a num-
ber of studies as the immune mediated process resulting in
secondary HLH. Some authors use the terms synonymously
whilst others have defined MAS as a subtype of secondary
HLH [13–15]. Primary HLH incorporates familial HLH
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(fHLH) and HLH caused by genetic immune deficiencies
such as Chediak-Higashi and X-linked lympoproliferative
disorder [14]. Differentiating between the primary and im-
munological cause is important for management options
and prognosis. In particular, a diagnosis of primary disease
carries the burden of treatment ending in haemopoeitic
stem cell transplant and genetic counselling, compared to
secondary disease which requires management of the
underlying autoimmune process [16, 17].
The pathophysiology underlying macrophage activation
syndrome is considered to be an excessive activation of ma-
ture macrophages and T-lymphocytes [18]. These macro-
phages infiltrate the bone marrow and inactivate cytotoxic
T-cell function and natural killer cells, leading to an ex-
treme overproduction of uncontrollable pro-inflammatory
cytokines. Studies have correlated clinical symptoms and
biological markers of MAS to an overproduction of IL-18
and the imbalance between IL-18 and IL-18 binding pro-
tein (the natural inhibitor) [19, 20]. Studies have also found
IL-10 and IFN-γ have important roles in disease patho-
physiology and severity of MAS [21, 22].
Coeliac Disease (CD) is an immune mediated condition
precipitated by gluten and gluten products in patients with
a genomic predisposition of HLA-DQ2 or HLA-DQ8. The
condition is confirmed by having anti-tissue transglutami-
nase (anti-tTG) antibodies and anti-endomysium antibodies
(EMA) or histological evidence of duodenal inflammation,
crypt hyperplasia and villous atrophy [23]. Strict criteria for
the diagnosis of CD has been made by European Society
for Paediatric Gastroenterology, Hepatology and Nutrition
(ESPGHAN) as diagnosing a patient carries a lifelong gluten
free diet. The criteria also outlines the necessary screen for
symptomatic patients when a biopsy is not performed, i.e.
significant anti-tTG and anti-EMA on a background of
HLA-DQ2/8 positivity [24]. For IgA anti-tTG and anti-
EMA the high sensitivity (98 and 95% respectively) and
specificity (98 and 99%), moderate positive predicted values
of (72 and 83%) and high negative predicted values (99 and
99%) make these autoantibodies useful markers for cor-
rectly detecting CD [25]. The inflammatory marker ferritin
has also been used to tease out differences in patients
with CD on a normal diet with those on a gluten-free
diet. Patients with CD on normal diet have a significantly
lower ferritin levels and higher soluble transferrin re-
ceptor [26, 27]. Children with CD can present with very
subtle signs, therefore having a robust screening criteria
is extremely important in aiding a difficult clinical
diagnosis.
Case Presentation
A six year and eleven month old girl of non-consanguineous
Caucasian parents first presented with a two week his-
tory of fever, weight loss, arthralgia and maculopapular
rash. She was born at term via Caesarean section with
no neonatal concerns. Her medical history was fairly
unremarkable, with mild eczema and croup and normal
growth. There was no family history of autoimmune con-
ditions. She was up-to-date with her immunizations. She
was initially diagnosed with tonsillitis which was positive
for Streptococcus on a throat swab. She remained unwell
despite recurrent courses of antibiotics over a 6 week
period. A comprehensive viral surveillance including Ep-
stein Barr Virus (EBV), Cytomegalovirus (CMV), HIV and
Hepatitis B using PCR on blood was negative on admis-
sion. She attended her local hospital due to persisting
symptoms. She had no clinical features of arthritis or
bowel disease. Serum inflammatory markers were promin-
ent including C-Reactive Protein 135 mg/l (0-10 mg/l),
thrombocytopenia with a platelet count of 64 × 109/l
(150–300 × 109/l), raised alanine transaminase (ALT),
1038 IU/l (10–35 IU/l), raised lactate dehydrogenase
(LDH), 8775 IU/L (420–750 IU/l), hyperferritinaemia,
71,378 μg/l (23–76 μg/l), hypofibrinogenaemia, 1 g/l
(1.5–4.0 g/l). Her haemoglobin (Hb) and white cell
count (WCC) were 80 g/L (115–155 g/l) and 5.1 × 109/l
(4.5–13.51 × 109/l) respectively. She was referred for
further investigation; her bone marrow biopsy showed
occasional haemophagocytosis; flow cytometry perforin ex-
pression was present, there was normal granule release
(CD107a) on activation of CD8 and NK cells and her
CD56 + ve cells were normal (82.4%) compared to the
control (71.5%). A basic auto-immune screen was negative
(anti-neutrophil cytoplasmic antibodies (ANCA), rheuma-
toid factor, anti-nuclear antibodies (ANA), anti-double-
stranded DNA (anti-dsDNA), and anti-cyclic citrullinated
peptide (anti-CCP)). A presumed diagnosis of secondary
HLH was made as she fulfilled HLH criteria without any
genetic cause with normal granule release. She was treated
with dexamethasone (8 weeks), etoposide (12 weeks),
cyclosporine A (weaned from 7 months) as per HLH
2004 protocol. She made a good recovery, her biochem-
ical markers normalised (ferritin 42 μg/l, CRP <5 mg/l,
ALT 26 IU/ml, platelets 260 x 109/l, Hb 120 g/l) and she
remained well for 20 months.
She subsequently represented with a HLH relapse hav-
ing been unwell for 2 weeks with headaches and lethargy
and 5-days of fever. Due to her previous medical history
she was screened for a relapse of secondary HLH. Serum
ferritin level was 6702 μg/l and LDH 1002 u/l. Repeat
bone marrow aspirate showed no evidence of haemo-
phagocytosis. She continued to have quotidian fevers oc-
curring in the evening and night for over a month with
other similar symptoms to the initial presentation,
arthralgia, a migratory erythematous rash, lethargy
and significant weight loss of 2 kg. A skin biopsy showed
neutrophilic leucocytoclastic vasculitis therefore she was
further investigated by paediatric rheumatology for an
underlying systemic condition with an angiogram which
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showed no specific evidence of vasculitis. Further auto-
antibody screening detected a raised anti-tissue transgluta-
minase (anti-TTG) at 108U/ml (0–6.9U/ml) and positive
anti-endomysial antibodies (anti-EMA) indicating a posi-
tive coeliac screen. Her HLA typing was positive for HLA-
DQ2 but negative for HLA DQ8. She was too unwell to
tolerate an endoscopy and jejunal biopsy. There had been
no abdominal symptoms and there was no family history
of Coeliac Disease. She commenced a gluten-free diet
without any Disease Modifying Anti-Rheumatic Drugs
(DMARDs) or biological agents, after which her symp-
toms dramatically improved with her energy levels rising
to 90% of normal, however, the rash took longer to fade.
Her biochemical markers also improved with her anti
TTG level normalising to 4.3U/ml and her ESR reducing
from 34 mm/h to 12 mm/h (<13 mm/h) within a month
of a gluten free diet. She remained extremely sensitive to
gluten, any exposure caused a reaction within a few hours
with fevers lasting up to seven days. This suggested that
the driving factor for her inflammatory process was due to
Coeliac Disease. In light of her hypersensitivity and severe
clinical condition, it was felt that a re-challenge with glu-
ten was not appropriate.
Since establishing a gluten-free diet she remained well
with no further episodes of MAS. However, after 3 years
of commencing a gluten free diet she developed swelling
of her joints and was diagnosed with arthritis, mainly af-
fecting the left elbow, which required joint injections
and treatment with methotrexate. The family have noted
that her symptoms correlate with mistakenly eaten food
containing gluten. At no point has she had any bowel
symptoms. There was no active arthritis, morning stiff-
ness or limping during either episode of MAS, making
SoJIA unlikely. A jejunal biopsy has not been carried out
as she has remained on a strict gluten-free diet. Care
was provided by a multi-professional team of rheumatol-
ogists, gastroenterologists and haematologists.
Discussion
Macrophage activation syndrome remains a serious con-
dition which can be easily missed unless there is a high
index of suspicion. The striking mortality associated with
MAS makes it an important differential for patients with
symptoms of systemic inflammation. Previous studies have
indicated a relationship between MAS and auto-immune
diseases in particular SoJIA, SLE, autoinflammatory (fever)
syndromes and Kawasaki disease. There is evidence that
Coeliac Disease is associated with other autoimmune con-
ditions such as JIA, type I diabetes mellitus and thyroid
disease [28–31]. This case report indicates that coeliac
disease can trigger the pro-inflammatory process of
macrophage activation.
The pathophysiology of both CD and MAS have not
been fully established, therefore only a presumptive
mechanism to connect the two conditions can be formed.
The mucosal damage is not only caused by components of
gluten but also directly by intraepithelial lymphocytes and
other immune mediated cells including macrophages and
natural killer cells [32]. Once these cells are activated the
positive feedback to regulate them becomes disorganised,
chaotic and invades the bone marrow leading to haemo-
phagocytosis. The underlying question is what triggers the
autoimmune process, and more importantly why does it
become chaotic in some patients? The theoretical answer
of a genetic predisposition, such as perforin or Munc-2
deficiency, followed by an environmental trigger needs
more research and evaluation.
Coeliac Disease can present insidiously with symptoms
differing between those under 3 years and those over
3 years old [33]. Symptoms of children under 3 years are
predominantly gastrointestinal related (diarrhoea, consti-
pation, abdominal pain and failure to thrive) whilst those
over 3 years of age are generally extra-gastrointestinal, in-
cluding screening of high risk children, abnormal blood
results (iron deficiency anaemia, high transaminases) and
other symptoms of short stature, alopecia and mood disor-
ders [34]. This results in difficulty in recognising CD and
potential delayed diagnosis [35]. Therefore, the challenge
of diagnosing CD together with the strong association
with other autoimmune diseases should prompt CD
screening in rheumatological patients.
The recently updated 2016 classification criteria for
MAS complicating SoJIA provides some assistance for
the potential diagnosis of MAS complicating CD. The
expert panel together with patient data found that 98.9%
of patients with a confirmed diagnosis of MAS had fever
at disease onset.[12] This has become essential in the
diagnosis of MAS. In contrast, fever does not feature as
a clinical symptom at diagnosis of CD [33, 36–38]. Patients
with CD who present with prolonged fever of unknown ori-
gin should be evaluated for MAS by a thorough examin-
ation and measurement of biochemical markers as outlined
by the HLH-2004 criteria [11]. Further validation of the
2016 classification criteria for MAS complicating SoJIA
may provide a better platform for diagnosis of MAS in
autoimmune disease in the future.
Conclusion
Macrophage activation syndrome is a severe autoimmune
disease of chaotic immune dysregulation that requires
early aggressive treatment. We present the first case report
that links macrophage activation syndrome to Coeliac
Disease and highlights the challenge of diagnosing Coeliac
Disease with unusual features such as associated pro-
longed fever. In managing patients with macrophage
activation syndrome, clinicians should have a low
threshold for screening children for other autoimmune
diseases including Coeliac Disease.
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